Instinct Bio named CelSiege representative for IN01 cancer immunotherapy in Japan, China

Instinct Bio has been appointed as CelSiege Biosciences' non-exclusive authorized representative for the IN01 cancer immunotherapy in Japan and China. The mandate covers facilitating introductions to potential partners, investors, and pharma groups, as well as early talks on licensing, co-development, clinical development, manufacturing, and commercialization. The Letter of Authorization was signed on September 18, 2026.

Instinct Bio was appointed CelSiege Biosciences’ non-exclusive authorized representative for IN01 cancer immunotherapy in Japan, China. * Mandate covers introductions to potential partners, investors, pharma groups, medical institutions, research organizations, investment funds. * Scope includes facilitating early talks on licensing, co-development, clinical development, manufacturing, commercialization. * Letter of Authorisation was signed Sept. 18, 2026; any transaction requires separate negotiations, due diligence, definitive agreements. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Instinct Bio Technical Company Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112508), on October 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

BIOT